Literature DB >> 11021823

Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo.

C Langdon1, C Kerr, M Hassen, T Hara, A L Arsenault, C D Richards.   

Abstract

Oncostatin M (OSM) is a multifunctional cytokine, a member of the interleukin-6/leukemia inhibitory factor (IL-6/LIF) family, that can regulate a number of connective-tissue cell types in vitro including cartilage and synovial tissue-derived fibroblasts, however its role in joint inflammation in vivo is not clear. We have analyzed murine OSM (muOSM) activity in vitro and in vivo in mouse joint tissue, to determine the potential role of this cytokine in local joint inflammation and pathology. The effects of muOSM and other IL-6/LIF cytokines on mouse synovial fibroblast cultures were assessed in vitro and showed induction of monocyte chemotactic protein-1, interleukin-6, and tissue inhibitor metalloproteinase-1, as well as enhancement of colony growth in soft agarose culture. Other IL-6/LIF cytokines including IL-6, LIF, or cardiotrophin-1, did not have such effects when tested at relatively high concentrations (20 ng/ml). To assess effects of muOSM in articular joints in vivo, we used recombinant adenovirus expressing muOSM cDNA (AdmuOSM) and injected purified recombinant virus (10(6) to 10(8) pfu) intra-articularly into the knees of various mouse strains. Histological analysis revealed dramatic alterations in the synovium but not in synovium of knees treated with the control virus Ad-dl70 or knees treated with Adm-IL-6 encoding biologically active murine IL-6. AdmuOSM effects were characterized by increases in the synovial cell proliferation, infiltration of mononuclear cells, and increases in extracellular matrix deposition that were evident at day 4, but much more marked at days 7, 14, and 21 after administration. The synovium took on characteristics similar to pannus and appeared to contact and invade cartilage. Collectively, these results provide good evidence that OSM regulates synovial fibroblast function differently than other IL-6-type cytokines, and can induce a proliferative invasive phenotype of synovium in vivo in mice on overexpression. We suggest that OSM may contribute to pathology in arthritis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021823      PMCID: PMC1850181          DOI: 10.1016/S0002-9440(10)64634-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

Review 1.  Rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Cell       Date:  1996-05-03       Impact factor: 41.582

2.  Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium.

Authors:  S J Sawchuk; G P Boivin; L E Duwel; W Ball; K Bove; B Trapnell; R Hirsch
Journal:  Hum Gene Ther       Date:  1996-03-01       Impact factor: 5.695

3.  Activation of the JAK-STAT signal transduction pathway by oncostatin-M cultured human and mouse osteoblastic cells.

Authors:  J B Levy; C Schindler; R Raz; D E Levy; R Baron; M C Horowitz
Journal:  Endocrinology       Date:  1996-04       Impact factor: 4.736

4.  Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of IL-6 induces lymphocytic hyperplasia in the lung.

Authors:  Z Xing; T Braciak; M Jordana; K Croitoru; F L Graham; J Gauldie
Journal:  J Immunol       Date:  1994-11-01       Impact factor: 5.422

5.  Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture.

Authors:  T E Cawston; A J Ellis; G Humm; E Lean; D Ward; V Curry
Journal:  Biochem Biophys Res Commun       Date:  1995-10-04       Impact factor: 3.575

Review 6.  Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1995-02

7.  Oncostatin M inhibits IL-1-induced expression of IL-8 and granulocyte-macrophage colony-stimulating factor by synovial and lung fibroblasts.

Authors:  C D Richards; C Langdon; F Botelho; T J Brown; A Agro
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

8.  Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway.

Authors:  A Yoshimura; M Ichihara; I Kinjyo; M Moriyama; N G Copeland; D J Gilbert; N A Jenkins; T Hara; A Miyajima
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

Review 9.  Biologic basis for interleukin-1 in disease.

Authors:  C A Dinarello
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

10.  Direct gene delivery to synovium. An evaluation of potential vectors in vitro and in vivo.

Authors:  I Nita; S C Ghivizzani; J Galea-Lauri; G Bandara; H I Georgescu; P D Robbins; C H Evans
Journal:  Arthritis Rheum       Date:  1996-05
View more
  27 in total

1.  Identification of two new arthritis severity loci that regulate levels of autoantibodies, interleukin-1β, and joint damage in pristane- and collagen-induced arthritis.

Authors:  Max Brenner; Teresina Laragione; Anish Shah; Adriana Mello; Elaine F Remmers; Ronald L Wilder; Pércio S Gulko
Journal:  Arthritis Rheum       Date:  2012-05

Review 2.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

3.  Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand.

Authors:  Alfons S K de Hooge; Fons A J van de Loo; Miranda B Bennink; Diana S de Jong; Onno J Arntz; Erik Lubberts; Carl D Richards; Wim B vandDen Berg
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 4.  gp130 at the nexus of inflammation, autoimmunity, and cancer.

Authors:  J S Silver; C A Hunter
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

5.  Oncostatin M and its role in fibrosis.

Authors:  Lukasz Stawski; Maria Trojanowska
Journal:  Connect Tissue Res       Date:  2018-07-30       Impact factor: 3.417

Review 6.  Lessons from animal models of arthritis.

Authors:  Wim B Van den Berg
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

7.  Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice.

Authors:  Emma C Walker; Narelle E McGregor; Ingrid J Poulton; Melissa Solano; Sueli Pompolo; Tania J Fernandes; Matthew J Constable; Geoff C Nicholson; Jian-Guo Zhang; Nicos A Nicola; Matthew T Gillespie; T John Martin; Natalie A Sims
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

8.  Fuzzy clustering analysis of osteosarcoma related genes.

Authors:  Kai Chen; Dajiang Wu; Yushu Bai; Xiaodong Zhu; Ziqiang Chen; Chuanfeng Wang; Yingchuan Zhao; Ming Li
Journal:  Pathol Oncol Res       Date:  2013-11-30       Impact factor: 3.201

9.  Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model.

Authors:  Andrew D Rowan; Wang Hui; Tim E Cawston; Carl D Richards
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

10.  Activation of Toll-Like Receptor 3 Induces Interleukin-1 Receptor Antagonist Expression by Activating the Interferon Regulatory Factor 3.

Authors:  Yang Liu; Chun-Fen Mo; Xing-Yan Luo; Hua Li; Hui-Jie Guo; Hai Sun; Song Hu; Li-Mei Li; Yan-Tang Wang; Shu-Xia Yang; Shan Chang; Qiang Zou
Journal:  J Innate Immun       Date:  2019-12-20       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.